Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 969,594
  • Shares Outstanding, K 17,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,890 K
  • 60-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.32
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.35
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.22 +27.60%
on 01/14/20
60.64 -4.85%
on 12/30/19
-2.45 (-4.07%)
since 12/27/19
3-Month
38.07 +51.56%
on 10/28/19
66.50 -13.23%
on 12/09/19
+19.56 (+51.28%)
since 10/25/19
52-Week
18.50 +211.89%
on 03/14/19
66.50 -13.23%
on 12/09/19
+34.53 (+149.03%)
since 01/25/19

Most Recent Stories

More News
Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility

Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking of the second commercial gene therapy facility in Findlay Township,...

KRYS : 57.34 (+2.36%)
Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer

Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly created position of chief commercial...

KRYS : 57.34 (+2.36%)
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

KRYS : 57.34 (+2.36%)
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

CGEN : 6.84 (+3.64%)
EPZM : 21.61 (-3.53%)
ACAD : 40.32 (+2.49%)
CUE : 15.38 (+1.12%)
KRYS : 57.34 (+2.36%)
5 Biotech Stocks Up More Than 100% This Year So Far

The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

EPZM : 21.61 (-3.53%)
CGEN : 6.84 (+3.64%)
ACAD : 40.32 (+2.49%)
KRYS : 57.34 (+2.36%)
CUE : 15.38 (+1.12%)
Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).

KRYS : 57.34 (+2.36%)
Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish...

KRYS : 57.34 (+2.36%)
Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

KRYS : 57.34 (+2.36%)
Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results

Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, "B-VEC")

KRYS : 57.34 (+2.36%)
Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ("bercolagene telserpavec," "B-VEC")

-- Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adverse events reported.

KRYS : 57.34 (+2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade KRYS with:

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

2nd Resistance Point 57.94
1st Resistance Point 56.98
Last Price 57.34
1st Support Level 54.90
2nd Support Level 53.79

See More

52-Week High 66.50
Last Price 57.34
Fibonacci 61.8% 48.16
Fibonacci 50% 42.50
Fibonacci 38.2% 36.84
52-Week Low 18.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar